Want to see NEO full AI Analyst Report?
NeoGenomics (NEO) Stock Statistics & Valuation Metrics
Total Valuation
NeoGenomics has a market cap or net worth of $2.18B. The enterprise value is $2.67B.
- Market Cap
- $2.18B
- Enterprise Value
- $2.67B
Share Statistics
NeoGenomics has 129,389,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 129,389,470
- Owned by Insiders
- 0.82%
- Owned by Institutions
- 64.10%
Financial Efficiency
NeoGenomics’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -5.07%.
- Return on Equity (ROE)
- -0.13
- Return on Assets (ROA)
- -0.08
- Return on Invested Capital (ROIC)
- -5.07%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 290.93K
- Profits Per Employee
- -43.21K
- Employee Count
- 2,500
- Asset Turnover
- 0.53
- Inventory Turnover
- 15.57
Valuation Ratios
The current PE Ratio of NeoGenomics is -69.49. NeoGenomics’s PEG ratio is -0.53.
- PE Ratio
- -69.49
- PS Ratio
- 2.83
- PB Ratio
- 2.75
- Price to FCF
- -78.13
- Price to Operating Cash Flow
- 515.25
- PEG Ratio
- -0.53
Income Statement
In the last 12 months, NeoGenomics had revenue of 727.33M and earned -108.03M in profits. Earnings per share was -0.84.
- Revenue
- 727.33M
- Gross Profit
- 282.54M
- Operating Income
- -66.08M
- Pretax Income
- -110.27M
- Net Income
- -108.03M
- EBITDA
- -38.69M
- Earnings Per Share (EPS)
- -0.84
Cash Flow
In the last 12 months, operating cash flow was 4.28M and capital expenditures -32.86M, giving a free cash flow of -28.58M billion.
- Operating Cash Flow
- 4.28M
- Free Cash Flow
- -28.58M
- Free Cash Flow per Share
- -0.22
Dividends & Yields
NeoGenomics pays an annual dividend of $0.40, resulting in a dividend yield of ―
- Dividend Per Share
- $0.40
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.28%
- Earnings Yield
- -1.46%
Stock Price Statistics
- Beta
- 1.18
- 52-Week Price Change
- 69.80%
- 50-Day Moving Average
- 17.69
- 200-Day Moving Average
- 12.80
- Relative Strength Index (RSI)
- 49.71
- Average Volume (3m)
- 1.99M
Important Dates
NeoGenomics upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 23, 2027
- Ex-Dividend Date
- Dec 17, 2020
Financial Position
NeoGenomics as a current ratio of 4.26, with Debt / Equity ratio of 56.45%
- Current Ratio
- 4.26
- Quick Ratio
- 3.94
- Debt to Market Cap
- 1.36
- Net Debt to EBITDA
- -8.08
- Interest Coverage Ratio
- -17.61
Taxes
In the past 12 months, NeoGenomics has paid -2.24M in taxes.
- Income Tax
- -2.24M
- Effective Tax Rate
- 0.02
Enterprise Valuation
NeoGenomics EV to EBITDA ratio is 78.80, with an EV/FCF ratio of -88.97.
- EV to Sales
- 3.23
- EV to EBITDA
- 78.80
- EV to Free Cash Flow
- -88.97
- EV to Operating Cash Flow
- 594.16
Balance Sheet
NeoGenomics has $139.28M in cash and marketable securities with $449.14M in debt, giving a net cash position of -$309.86M billion.
- Cash & Marketable Securities
- $139.28M
- Total Debt
- $449.14M
- Net Cash
- -$309.86M
- Net Cash Per Share
- -$2.39
- Tangible Book Value Per Share
- $0.10
Margins
Gross margin is 43.80%, with operating margin of -5.98%, and net profit margin of -4.10%.
- Gross Margin
- 43.80%
- Operating Margin
- -5.98%
- Pretax Margin
- -4.59%
- Net Profit Margin
- -4.10%
- EBITDA Margin
- 4.10%
- EBIT Margin
- -4.18%
Analyst Forecast
The average price target for NeoGenomics is $24.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $24.71
- Price Target Upside
- 44.11% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- 11.08%
- EPS Growth Forecast
- 71.76%
Scores
- Smart Score
- 8
- AI Score
- 55
